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Marine sponges of the Irciniidae family contain both bioactive furanosesterterpene tetronic acids (FTAs) and prenylated
hydroquinones (PHQs). Both classes of compounds are known for their anti-inflammatory, antioxidant, and antimicrobial
properties and known to display growth inhibitory effects against various human tumor cell lines. However, the different
experimental conditions of the reported in vitro bioassays, carried out on different cancer cell lines within separate studies, prevent
realistic actual discrimination between the two classes of compounds from being carried out in terms of growth inhibitory effects.
In the present work, a chemical investigation of irciniid sponges from Tunisian coasts led to the purification of three known FTAs
and three known PHQs. The in vitro growth inhibitory properties of the six purified compounds have been evaluated in the same
experiment in a panel of five human and onemurine cancer cell lines displaying various levels of sensitivity to proapoptotic stimuli.
Surprisingly, FTAs andPHQs elicited distinct profiles of growth inhibitory-responses, differing by one to two orders ofmagnitude in
favor of the PHQs in all cell lines.The obtained comparative results are discussed in the light of a better selection of drug candidates
from natural sources.
1. Introduction
The great majority of cancer patients (i.e., ∼90%) die from
their metastases because metastatic cancers are resistant to
almost any type of currently available treatment [1, 2], while
the survival rates of patients with metastatic or recurrent
cancers have remained virtually unchanged during the past
30 years [2]. Cancer cells and especially metastatic cancer
cells resist cytotoxic insults throughmultiple and biologically
complex mechanisms including dual roles for autophagy
[3], the so-called multidrug resistance (MDR) phenotype
[4, 5], cancer cell dormancy [6, 7], cancer stem cells [8,
9], an extraordinary sophisticated tumor microenvironment
[10–12], hypoxia [13], and also the resistance to proapoptotic
stimuli [14, 15]. There is thus urgent need for new effective
drugs in oncology that could face the extraordinary complex
phenomenon of the metastatic process. In this area of
research, the exploration of the nature chemical diversity
still remains a major option to select the best candidates
as novel therapeutics against metastatic cancers. In general,
initial selection of promising bioactive products is made by
evaluating their in vitro growth inhibitory activity.
Among the richest natural sources of candidates as
potential anticancer agents, marine sponges (phylum Pori-
fera) already provided a wide range of cytotoxic metabo-
lites with peculiar chemical structures. This report, in
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Table 1: Structures of compounds 1–6, natural sources, and sampling sites in Tunisia.
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O
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Sarcotragus spinosulus Schmidt, 1862 Tabarka
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O
Sarcotragus fasciculatus (Pallas, 1766) Monastir
(S)
O
OH
O3 (variabilin)
Sarcotragus fasciculatus (Pallas, 1766) Monastir
4
OH
OH
6
H
Sarcotragus spinosulus Schmidt, 1862 Monastir
5
OH
OH
7
H
Sarcotragus spinosulus Schmidt, 1862 Tabarka
6
OH
OH
OH
H
6 Sarcotragus foetidus Schmidt, 1862 Bizerte
particular, focuses on compounds isolated from sponges
of the genera Ircinia and Sarcotragus (Demospongiae: Dict-
yoceratida: Irciniidae).
Two major classes of compounds from irciniid sponges
have especially attracted the attention ofmarine natural prod-
uct chemists and pharmacologists: (a) linear terpenes con-
taining both a furan ring and the tetronic acid moiety (FTAs)
and (b) hydroquinones with a terpenoid portion (PHQs).
Although it is still not clear whether the compounds are of
dietary origin, produced by microbial symbionts, or de novo
biosynthesized by the sponges themselves, a panel of bioactiv-
ities with pharmaceutical potential, including cytotoxic, anti-
inflammatory, antioxidant, and antimicrobial properties,
have been attributed to both classes of compounds [16–26]. It
is worth mentioning, however, that compounds belonging to
the two different groups of compounds isolated from irciniid
sponges have not yet been compared in the same study using
the same experimental procedures for growth inhibition
assessments against the same panel of cancer cell lines, thus
preventing from establishing reliable differences between
themselves, at least in vitro, in terms of potential anticancer
effects.
The following is a report on our experiments aimed
at potency discrimination between compounds belonging
to both classes of compounds in terms of in vitro growth
inhibition in a panel of six cancer cell lines with dis-
tinct levels of biological aggressiveness as translated by
distinct levels of sensitivity to proapoptotic stimuli. The
research is thus especially aimed at assessing at which
extent the different chemical features of the isolated com-
pounds affect their in vitro growth inhibitory activities
and if the patterns of in vitro growth inhibition of these
compounds are similar to the ones displayed by clas-
sical cytotoxic proapoptotic ones. In other words, we
explored the ability of the metabolites to induce cell death
pathways that are mechanistically distinct from apoptosis
[27, 28].
Wefirst isolated compounds 1–6 (Table 1) from samples of
Sarcotragus fasciculatus (Pallas, 1766), Sarcotragus spinosulus
Schmidt, 1862, and Sarcotragus foetidus Schmidt, 1862, col-
lected along Tunisian coasts. Subsequently, to evaluate the
growth inhibitory activities of the purified natural products,
we have tried to recapitulate one of the characteristics
of metastatic cancer cells, that is, their ability to resist
proapoptotic cytotoxic insults, while using established cancer
cell lines developing alone in plastic flasks. We have thus
chosen six cancer cell lines (five human and one murine
ones) with distinct levels of sensitivity to proapoptotic
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stimuli to determine the in vitro growth inhibitory activity
of compounds 1–6. The selected human MCF-7 mammary
adenocarcinoma [29] and Hs683 oligodendroglioma [30, 31]
cell lines display actual sensitivity to proapoptotic stimuli,
as does also the mouse B16F10 melanoma model [32, 33].
The remaining three human cancer cell lines display various
levels of resistance to proapoptotic stimuli and they included
the A549 non-small-cell lung cancer (NSCLC) [34], the
SKMEL-28 melanoma [33], and the U373 glioblastoma [30,
31]. The growth inhibitory effects induced by compounds
1–6 on these six cancer cell lines were determined by
means of the MTT colorimetric assay as detailed previously
[29–35].
2. Materials and Methods
2.1. General Experimental Procedures. NMR experiments
were recorded at ICB-NMR Service Centre on a DRX
600MHz Bruker spectrometer equipped with a TXI Cry-
oProbe, on a Bruker Avance-400 spectrometer using an
inverse probe fitted with a gradient along the 𝑧-axis, and
on a Bruker DPX-300 spectrometer. The NMR spectra were
acquired in CDCl3 and in CD3OD. ESIMS and HRESIMS
spectra were measured on a Micromass Q-TOF Microspec-
trometer coupled with HPLC Waters Alliance 2695. The
instrument was calibrated by using a PEG mixture from 200
to 1000MW. Optical rotations were measured using a Jasco
DIP 370 digital spectropolarimeter. Analytical and prepara-
tiveTLCwere performedonprecoated silica gel plates (Merck
Kieselgel 60 F254, 0.2mm and 0.5mm), with detection
provided by UV light (254 nm) and by spraying with ceric
sulfate (CeSO
4
) reagent followed by heating (120∘C). Silica
gel column chromatography was performed using Merck
Kieselgel 60 powder whereas size-exclusion chromatography
was achieved on Sephadex LH-20 column.
2.2. Sponge Material and Taxonomic Identification. Four
samples of three irciniid sponge species were collected by
using SCUBA diving at a depth of about 15m from three
different sites along the coast of Tunisia. In particular,
S. spinosulus was collected from Tabarka (36∘58󸀠3.65󸀠󸀠N,
8∘45󸀠53.89󸀠󸀠E) and Monastir (35∘46󸀠25.00󸀠󸀠N, 10∘50󸀠20.35󸀠󸀠E)
in November 2010, S. fasciculatus (Pallas, 1766) was collected
from Monastir in November 2010, while S. foetidus was
collected from Cap Zebib (37∘15󸀠35.38󸀠󸀠N, 10∘04󸀠46.05󸀠󸀠E) in
June 2011. The samples were kept frozen at −20∘C until the
extraction process.The colors of the sampleswere blackish for
S. foetidus and S. spinosulus and red-brown for S. fasciculatus,
with white-to-beige interior. The specimens were irregularly
massive with a subspherical shape. The texture was resistant
to tearing or cutting, with a firm and compressible consis-
tency. The ectosome was thick and coarsely conulose. For
taxonomic identification, sponge samples were preserved in
70% alcohol. Preparations of skeletons followed the standard
practice proposed by Ru¨tzler [36]. The classification used in
this work was that proposed by Hooper and van Soest [37],
with the amendments given in the World Porifera Database
[38]. The skeleton of the different species was a system
of primary and secondary fibers that consists of laminated
primary and secondary fibers and comprises numerous and
fine spongin filaments. The diameter of primary fiber, sec-
ondary fiber, and spongin were, respectively, 100 𝜇m, 30 𝜇m,
and 5 𝜇m for S. foetidus; 80 𝜇m, 40 𝜇m, and 0.7𝜇m for S.
fasciculatus; and 70 𝜇m, 30 𝜇m, and 2 𝜇m for S. spinosulus.
2.3. Extraction and Purification. Each sponge sample was
exhaustively extracted with acetone at room temperature.
After evaporation of the solvent in vacuo, the remaining
aqueous phases were separately partitioned between H
2
O
and Et
2
O.The Et
2
Oportions from each extraction were evap-
orated under reduced pressure affording the corresponding
crude Et
2
O extracts.
A portion (2 g) of the Et
2
O extract (3 g) of S. spinosulus
from Tabarka was first fractionated on Sephadex LH-20
column (CHCl
3
/MeOH, 1 : 1) to give a fraction containing
ircinin 1 (1) and compound 5 as main metabolites. This
fraction (546.0mg) was then purified on silica gel column
eluted with a gradient solvent system ranging from 100% to
20% light petroleum ether in Et
2
O to give pure compound 5
(33.8mg) [39] and ircinin 1 [1, 53.1mg; [𝛼]D + 27.5 (𝑐 = 6.7,
CHCl
3
); and [𝛼]D + 16.5 (𝑐 = 6.7, MeOH)] [16, 40, 41].
The Et
2
O extract (846.6mg) of S. spinosulus fromMonas-
tir was fractionated on silica gel column elutedwith a gradient
solvent system ranging from 100% to 20% of light petroleum
ether in Et
2
O affording a fraction (57.4mg) containing com-
pound 4. An aliquot (15.2mg) of this fraction was further
purified onpreparative TLC (light petroleumether/Et
2
O, 1 : 1)
obtaining 12mg of pure compound 4 [39].
An aliquot (2 g) of Et
2
O extract (8 g) from S. fasciculatus
collected off the coast of Monastir was first subjected to
Sephadex LH-20 column (CHCl
3
/MeOH, 1 : 1) affording a
major fraction (500mg) which was purified on silica gel
column eluted with a gradient solvent system ranging from
80% to 30% of light petroleum ether in Et
2
O. Two selected
fractions (40mg and 60mg) from this column containing
sarcotin A (2) [16, 42] and variabilin (3) [43, 44], respectively,
were further subjected to preparative TLC purification to give
pure 2 [15.5mg; [𝛼]D +28.0 (𝑐 = 7.7, CHCl3); and [𝛼]D +17.5
(𝑐 = 7.7,MeOH)] and 3 [21.3mg; [𝛼]D−21.5 (𝑐 = 1.5, CHCl3);
and [𝛼]D − 10.5 (𝑐 = 1.5, MeOH)].
The Et
2
O extract (61.6mg) from S. foetidus was subjected
to silica gel column eluted with a gradient solvent system
ranging from 100% to 0% light petroleum ether in diethyl
ether affording pure compound 6 (4.6mg) [26].
All isolated compounds were identified by comparison
of their spectral data (see Supplementary Material, available
online at http://dx.doi.org/10.1155/2016/5318176) with the lit-
erature values [16, 26, 39–44].
2.4. Determination of In Vitro Anticancer Activity. The cell
lines that we used for the MTT colorimetric assay (Table 2)
are five human and one murine cancer cell lines with the
following histological types and origins. The human cancer
cell lines include the A549 NSCLC (DSMZ code ACC107),
the Hs683 oligodendroglioma (American Type Culture
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Table 2: GI
50
(𝜇M) values for compounds 1–6 against human and murine cancer cell lines.
Compound Human Murine Mean ± SEM
A549 Hs683 MCF-7 SKMEL-28 U373 B16F10
1 >100 94 67 >100 >100 73 >89
2 >100 >100 >100 >100 >100 66 >94
3 >100 >100 >100 >100 >100 77 >96
4 23 27 3 3 15 1 12 ± 5
5 34 45 5 4 48 4 23 ± 9
6 4 5 4 1 5 1 3 ± 1
GI50: in vitro concentration (𝜇M) needed to inhibit cell population growth by 50% after 72 hours of cell culture with the compound.
Collection (ATCC) code HTB-138), the MCF-7 breast ade-
nocarcinoma (Deutsche Sammlung von Mikroorganismen
und Zellkulturen (DSMZ) code ACC115), the SKMEL-28
melanoma (ATCC code HTB-72), and the U373 glioblas-
toma (European Collection of Cell Culture (ECACC) code
08061901) cell lines. The B16F10 mouse melanoma cell line
(ATCC code CRL-6475) was obtained from the ATCC
collection (Manassas, VA).
The cells were cultured in RPMI (Lonza, Verviers,
Belgium) medium supplemented with 10% heat inacti-
vated foetal calf serum (Lonza). All culture media were
supplemented with 4mM glutamine, 100 𝜇g/mL gentam-
icin, and 200U/mL penicillin and 200 𝜇g/mL streptomycin
(Lonza). The overall growth level of the human cancer cell
lines was determined using a colorimetric MTT (3-[4,5-
dimethylthiazol-2yl]-diphenyl tetrazolium bromide, Sigma,
Belgium) assay as detailed previously [29–32]. Compounds 1–
6 were dissolved in DMSO and redissolved in the cell culture
media at a final concentration of 0.1%, which induces no
observable toxic effects on cells. Six replicates of each exper-
imental condition were performed. Thus, this procedure
enables the concentration of compounds 1–6 that decreased
by 50% the growth of each cell line (GI
50
concentration) after
having cultured it with the compound of interest for 72 h (the
GI
50
index in 𝜇M) to be determined.
3. Results
The chemical study of irciniid sponges collected along
Tunisian coasts led to the isolation of the known FTAs
ircinin 1 (1), sarcotin A (2), and variabilin (3), along with
the known PHQs 4–6 (Table 1). The isolated compounds
were identified by comparison with 1H-NMR and 13C-NMR,
mass spectrometry, and optical rotation data available in the
literature [16, 26, 39–44].
Subsequently, we tested the in vitro growth inhibitory
activities of the isolated natural products from irciniid
sponges against six cancer cell lines and the obtained data are
illustrated in Table 2.
All PHQs showed GI
50
concentration <10 𝜇M on MCF-
7, SKMEL-28, and B16F10 cell lines, while just compound 6
displayed a homogeneous inhibitory pattern <10 𝜇M on all 6
cell lines tested. Conversely, the three FTAs showed higher
GI
50
concentration, always >60 𝜇M.
4. Discussion
Before proceeding to an interpretation of the data, we need to
define when the compounds can be considered remarkably
active with respect to the effects they produce on cancer
cells.TheGI
50
-relatedmicromolar concentrations that define
precisely the limits between “weakly active,” “active,” and
“highly active” compounds in terms of growth inhibition
are not following standardized rules in the literature. The
instructions for authors of the Journal of Natural Products
define as inactive a compound whose GI
50
concentration is
>10 𝜇M. The US National Cancer Institute (NCI, Bethesda,
MD) also tests for a given compound 10 𝜇M as its higher
potential growth inhibitory concentration. Consequently, if
we refer to these criteria, among the studied compounds
only compound 6 behaves actually as an inhibitor of cancer
cell growth independently of the levels of sensitivity to
proapoptotic stimuli of the various cancer cell lines under
study.
On the other hand, compounds 4 and 5 showed a very
similar pattern of growth inhibition with the most sensitive
cell lines being MCF-7, SKMEL-28, and B16F10, while their
growth inhibitory activity against the remaining three cell
lines was about one magnitude weaker. This evidence seems
to reflect the strong structural similarities among hepta- and
octaprenylhydroquinones 4 and 5, which just differ by one
isoprene unit (Table 1). In addition, the data in Table 2 clearly
indicate that FTAs and PHQs display quite distinct profiles in
terms of in vitro cancer growth inhibitory activity, differing
by one to two orders of magnitude in favor of the PHQs in all
cell lines. Although additional structure-activity relationship
(SAR) studies are necessary for accurate identification of the
structural features required for the activity of compound 6,
our finding suggests that the presence of a hydroxyl group
on the chain of 6 could be related to its enhanced growth
inhibitory activity on cancer cells as compared to the non-
hydroxylated 4 and 5. This finding, however, contrasts with
earlier findings indicating less efficiency of 6 compared to 4
and 5when tested against the chronic myelogenous leukemia
(CML) cell line K562 [26]. This apparent discrepancy could
mainly relate to the fact that Abed et al. [26] used one
leukemia cell line growing in suspension, while we made use
of six adherent cancer cell lines. As an example that we can
cite among many others and thanks to the help provided
by the NCI to characterize the mechanism of action of a
novel fungal-related metabolite, that is, sphaeropsidin A,
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we observed that the leukemia cell lines from the NCI 60-
cell line panel displayedmarkedly distinct profiles in terms of
growth inhibitionwhen compared, for example, tomelanoma
and kidney cancer cell lines [35]. The data from the current
study clearly point to the fact that (i) compound 6 (and to a
lesser extent compounds 4 and 5) markedly inhibits cancer
cell growth and that (ii) the 6-induced growth inhibition in
cancer cells is independent of the levels of resistance of the
cancer cells (at least the models under study) to proapoptotic
stimuli.
5. Conclusions
By comparing different metabolites isolated from sponges
belonging to the genus Sarcotragus, our study evidenced
higher in vitro growth inhibitory effects of PHQs on cancer
cell lines, compared to FTAs. In addition, our results suggest,
in spite of previous evidence reported in the literature, that
compound 6 is the most active among the tested PHQs,
inducing growth inhibition in cancer cells independent of
their levels of resistance to proapoptotic stimuli. Conse-
quently, 6 clearly deserves further in-depth analyses of its
anticancer mechanism of action, toward its possible use to
treat metastatic cancer.
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